Faculty

John C. Morris, III, M.D.

Clinical Studies

A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) (LIBRETTO-001) Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
The purpose of this first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of LOXO-292 administered orally to patients with advanced solid tumors, including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

LOXO-RET-18037: Expanded Access for the Treatment of Cancers with Rearranged During Transfection (RET) Activation Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.
The purpose of this study is to provide expanded access for patients with cancer with RET activation who are ineligible for an ongoing LOXO-292 clinical trial or have other considerations that prevent access to LOXO-292 through an existing clinical trial.